Lupus Low Disease Activity State As a Treatment Target for Pediatric Patients with Lupus Nephritis

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2022 Sep 26

PMID 36156735

Authors

Hakan Kisaoglu

Ozge Baba

Mukaddes Kalyoncu

Affiliations

Soon will be listed here.

Abstract

Background: Lupus low disease activity state (LLDAS) is a treatment target for patients with SLE and is associated with decreased risk for severe flare and new damage. We investigated the utility of the achievement of LLDAS in children with lupus nephritis and whether attainment of LLDAS is associated with more favorable outcomes.

Methods: Data of children, diagnosed with biopsy-proven lupus nephritis between January 2012 and December 2020, were retrospectively analyzed.

Results: For patients who did not achieve LLDAS after initial treatment (first 6 months), presence of autoimmune hemolytic anemia (62% vs. 18%, p = 0.047), anti-Sm (85% vs. 18%, p = 0.003) and anti-dsDNA (77% vs. 27%, p = 0.038) antibodies, proliferative lupus nephritis (77% vs. 27%, p = 0.038), and hypertension (69% vs. 9%, p = 0.005) at onset were more frequently encountered. Also, a lower rate of complete kidney response (43% vs. 100%, p = 0.005) and a higher rate of hypertension (86% vs. 13%, p = 0.002) were observed in patients who did not achieve LLDAS-50, defined as being in LLDAS at least 50% of the observation time. Attainment of both LLDAS after initial treatment and LLDAS-50 were associated with lower rates of kidney flare (p = 0.001 and p = 0.002, respectively) and damage accrual (p = 0.007 and p = 0.02, respectively) through the observation period.

Conclusions: LLDAS is an attainable treatment target for children with lupus nephritis and associated with lower rates of kidney flare and damage. Presence of hematologic involvement, hypertension, and proliferative lupus nephritis at onset adversely influenced the early achievement of LLDAS. A higher resolution version of the Graphical abstract is available as Supplementary information.

Citing Articles

Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort.

Hunnicutt J, Georgiou M, Richards A, Quasny H, Magder L, Goldman D Lupus Sci Med. 2024; 11(2.

PMID: 39663154 PMC: 11647352. DOI: 10.1136/lupus-2024-001206.

Early-onset lupus nephritis.

Peyronel F, Rossi G, Palazzini G, Odone L, Errichiello C, Emmi G Clin Kidney J. 2024; 17(8):sfae212.

PMID: 39135943 PMC: 11318049. DOI: 10.1093/ckj/sfae212.

Managing Lupus Nephritis in Children and Adolescents.

Chan E, Lai F, Ma A, Chan T Paediatr Drugs. 2023; 26(2):145-161.

PMID: 38117412 DOI: 10.1007/s40272-023-00609-3.

Lupus Nephritis in Children: Novel Perspectives.

Pennesi M, Benvenuto S Medicina (Kaunas). 2023; 59(10).

PMID: 37893559 PMC: 10607957. DOI: 10.3390/medicina59101841.

Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention.

Banos A, Bertsias G Curr Rheumatol Rep. 2023; 25(10):183-191.

PMID: 37452914 PMC: 10504124. DOI: 10.1007/s11926-023-01109-6.

References

Kamphuis S, Silverman E . Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010; 6(9):538-46. DOI: 10.1038/nrrheum.2010.121. View

Oni L, Wright R, Marks S, Beresford M, Tullus K . Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2020; 36(6):1377-1385. PMC: 8084759. DOI: 10.1007/s00467-020-04686-1. View

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

Groot N, de Graeff N, Marks S, Brogan P, Avcin T, Bader-Meunier B . European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017; 76(12):1965-1973. DOI: 10.1136/annrheumdis-2017-211898. View

Golder V, Tsang-A-Sjoe M . Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford). 2020; 59(Suppl5):v19-v28. PMC: 7719036. DOI: 10.1093/rheumatology/keaa420. View

Franklyn K, Lau C, Navarra S, Louthrenoo W, Lateef A, Hamijoyo L . Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2015; 75(9):1615-21. DOI: 10.1136/annrheumdis-2015-207726. View

Tselios K, Gladman D, Urowitz M . How can we define low disease activity in systemic lupus erythematosus?. Semin Arthritis Rheum. 2018; 48(6):1035-1040. DOI: 10.1016/j.semarthrit.2018.10.013. View

Wahadat M, van den Berg L, Timmermans D, van Rijswijk K, van Dijk-Hummelman A, Bakx S . LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med. 2021; 8(1). PMC: 8719245. DOI: 10.1136/lupus-2021-000571. View

Smith E, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M . Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2021; 61(8):3378-3389. PMC: 9348762. DOI: 10.1093/rheumatology/keab915. View

10.

Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A . Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017; 19(1):247. PMC: 5681839. DOI: 10.1186/s13075-017-1451-5. View

11.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

12.

Weening J, DAgati V, Schwartz M, Seshan S, Alpers C, Appel G . The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15(2):241-50. DOI: 10.1097/01.asn.0000108969.21691.5d. View

13.

Yu F, Haas M, Glassock R, Zhao M . Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017; 13(8):483-495. DOI: 10.1038/nrneph.2017.85. View

14.

Flynn J, Kaelber D, Baker-Smith C, Blowey D, Carroll A, Daniels S . Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3). DOI: 10.1542/peds.2017-1904. View

15.

Gladman D, Ibanez D, Urowitz M . Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. View

16.

Ruperto N, Hanrahan L, Alarcon G, Belmont H, Brey R, Brunetta P . International consensus for a definition of disease flare in lupus. Lupus. 2010; 20(5):453-62. DOI: 10.1177/0961203310388445. View

17.

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3):363-9. DOI: 10.1002/art.1780390303. View

18.

Hao Y, Oon S, Ji L, Gao D, Fan Y, Geng Y . Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clin Rheumatol. 2021; 41(2):357-366. PMC: 8782788. DOI: 10.1007/s10067-021-05940-z. View

19.

Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G . Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021; 30(13):2144-2150. DOI: 10.1177/09612033211054399. View

20.

Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H . Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol. 2021; 37(2):367-376. PMC: 8816762. DOI: 10.1007/s00467-021-05164-y. View